Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Infodemiology

Date Submitted: Oct 6, 2025
Open Peer Review Period: Oct 27, 2025 - Dec 22, 2025
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Mpox on Instagram: A content analytic study

  • Elizabeth E. Havron; 
  • Kylee Chenault; 
  • Danny Valdez; 
  • Rebecca F. Houghton; 
  • Eric R. Walsh-Buhi

ABSTRACT

Background:

Mpox was declared a public health emergency of international concern in 2022. Instagram is widely used by age groups and communities disproportionately affected by mpox, yet platform-specific evidence on mpox information characteristics and engagement is limited.

Objective:

To characterize sources, content, and engagement features of mpox-related Instagram posts, to describe prevention and treatment framing, and to compare the top 10% most-liked posts with the remaining corpus.

Methods:

We retrieved English-language public Instagram posts via CrowdTangle containing “mpox” or “monkeypox” dated May 5, 2022 to January 17, 2023 (initial N=18,616). Using a pretested, deductive codebook adapted from prior Instagram health studies, two coders completed two pilot rounds; variables with low agreement were excluded. Interrater reliability across retained variables showed mean κ=0.70 (median κ=0.83). A randomized analytic sample of N=1,000 posts was coded for source type, content features, and prevention/treatment framing. Descriptive statistics were computed. For engagement contrasts, we compared the top 10% most-liked posts with the bottom 90% using tests of differences in independent proportions (mean differences [MD] with p-values).

Results:

Most posts originated from organizations (76.0%) versus individuals (24.0%). Organizational sources most commonly included businesses (57.4%) and news/media outlets (52.8%); government (22.9%), nonprofits (17.3%), and health-care organizations (9.2%) were less frequent. About one-third of posts cited a source (34.4%), most often the WHO and CDC/other federal entity. Posts predominantly used illustrated images/infographics (82.7%); photos appeared in 47.3% and videos in 12.4% of posts. Prevention content appeared in 38.4% of posts, most commonly vaccination (68.5% of prevention posts), followed by avoiding close contact (14.5%), avoiding contact with objects (8.3%), abstaining from sexual activity (7.6%), and condom use (1.3%); 28.9% of prevention posts noted barriers. Treatment mentions were uncommon (2.5% traditional biomedical; 0.2% alternative). Compared with the bottom 90%, the top 10% most-liked posts: 1) were more likely to originate from public figures/celebrities among individuals (MD=-0.591; p<.001) and from businesses (MD=-0.299; p<.001) or news/media (MD=-0.350; p<.001) among organizations; 2) were less likely to be from government, nonprofit, or health-care organizations (all p<.01); and more often included non-moving images (MD=-0.119; p<.05), visible lesion depictions (MD=-0.081; p<.05), prevalence mentions (MD=-0.180; p<.001), and citations (MD=-0.162; p<.01).

Conclusions:

During the initial outbreak period, highly engaged mpox content on Instagram skewed toward posts by public figures and news/business accounts and toward static, citation-bearing visuals that included prevalence context and occasionally lesion imagery. Public-health communicators seeking reach on Instagram should prioritize clear static infographics with explicit source citation and epidemiologic context and consider co-publishing with trusted creators and news outlets, while addressing access barriers highlighted in prevention posts.


 Citation

Please cite as:

Havron EE, Chenault K, Valdez D, Houghton RF, Walsh-Buhi ER

Mpox on Instagram: A content analytic study

JMIR Preprints. 06/10/2025:85379

DOI: 10.2196/preprints.85379

URL: https://preprints.jmir.org/preprint/85379

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.